Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer

Breast Cancer Research and Treatment

Volumn 98, Issue 2, 2006, Pages 167-172

  Johansson, Harriet ^a   Bonanni, Bernardo ^a   Mariette, Frederique ^a   Cazzaniga, Massimiliano ^a   Baglietto, Laura ^c   Guerrieri Gonzaga, Aliana ^a   Sandri, Maria Teresa ^a   Luini, Alberto ^a   Pelosi, Giuseppe ^a,b   Decensi, Andrea ^a,d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CANCER EPIDEMIOLOGY CENTRE   (Australia)

^d GALLIERA HOSPITAL   (Italy)

Author keywords

Biomarkers; Bone resorption; Breast cancer; Chemoprevention; Estrogen; Raloxifene

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; PLACEBO; PRASTERONE SULFATE; RALOXIFENE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; ENDOCRINE SYSTEM; FEMALE; HORMONE BLOOD LEVEL; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

AGED; BREAST NEOPLASMS; COLLAGEN TYPE I; DEHYDROEPIANDROSTERONE SULFATE; DOUBLE-BLIND METHOD; FEMALE; GONADAL STEROID HORMONES; HUMANS; MIDDLE AGED; PEPTIDES; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEX HORMONE-BINDING GLOBULIN;

EID: 33745897345     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9145-0     Document Type: Article

References (38)

1. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637-645, 1999
2. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647, 1997
3. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279: 1445-1451, 1998
4. Cox DA, Sarkar S, Harper K, Barrett-Connor E: Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women. Curr Med Res Opin 20: 1049-1055, 2004
5. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L Jr: Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 95: 104-110, 2000
6. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281: 2189-2197, 1999
7. Goldstein SR: Update on raloxifene to prevent endometrial-breast cancer. Eur J Cancer 36 Suppl 4: S54-S56, 2000
8. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA: Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94: 14105-14110, 1997
9. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, CORE Investigators: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96: 1751-1761, 2004
10. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300, 2003
11. Vogel VG, Costantino JP, Wickerham DL, Cronin WM: National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res 9: 495S-501S, 2003
12. Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW Jr: Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88: 2047-2053, 2000
13. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien ME, Scott T, Muchmore DB: Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 10: 961-966, 2001
14. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, IMPACT Trialists: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11: 951s-958s, 2005
15. Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94: 606-616, 2002
16. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA, Multiple Outcomes of Raloxifene Evaluation (MORE) Trial: Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287: 216-220, 2002
17. Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR: Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 19: 3111-3116, 2001
18. Chailurkit LO, Ongphiphadhanakul B, Piaseu N, Saetung S, Rajatanavin R: Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratory. Clin Chem 47: 1083-1088, 2001
19. Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD: Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 27: 283-286, 2000
20. Kelloff GJ, Bast RC Jr., Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Woude GF: Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res 10: 3881-3884, 2004
21. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrisi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U: A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95: 779-790, 2003
22. Catalano MG, Frairia R, Boccuzzi G, Fortunati N: Sex hormone-binding globulin antagonizes the anti-apoptotic effect of estradiol in breast cancer cells. Mol Cell Endocrinol 230: 31-37, 2005
23. Genazzani AR, Lombardi I, Borgioli G, di Bono I, Casarosa E, Gambacciani M, Palumbo M, Genazzani AD, Luisi M: Adrenal function under long-term raloxifene administration. Gynecol Endocrinol 17: 159-168, 2003
24. Reindollar R, Koltun W, Parsons A, Rosen A, Siddhanti S, Plouffe L Jr, Study Group on the Effects of Raloxifene HCI With Low-Dose Premarin Vaginal Cream: Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity. Fertil Steril 78: 469-472, 2002
25. Bjarnason NH, Christiansen C: Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 26: 561-569, 2000
26. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J: Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34: 344-351, 2004
27. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C: Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31: 57-61, 2002
28. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C, Endogenous Hormones Breast Cancer Collaborative Group: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95: 1218-1226, 2003
29. Sowers M, Derby C, Jannausch ML, Torrens JI, Pasternak R: Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. J Clin Endocrinol Metab 88: 4904-4910, 2003
30. Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI, Postmenopausal Estrogen/Progestin Intervention Trial: Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the postmenopausal estrogen/progestin intervention trial. J Clin Endocrinol Metab 88: 1646-1652, 2003
31. Tufano A, Marzo P, Enrini R, Morricone L, Caviezel F, Ambrosi B: Anthropometric, hormonal and biochemical differences in lean and obese women before and after menopause. J Endocrinol Invest 27: 648-653, 2004
32. Lonning PE, Helle SI, Johannessen DC, Adlercreutz H, Lien EA, Tally M, Ekse D, Fotsis T, Anker GB, Hall K: Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clin Endocrinol (Oxf) 42: 23-30, 1995
33. Christodoulakos G, Lambrinoudaki I, Panoulis C, Sioulas V, Rizos D, Caramalis G, Botsis D, Creatsas G: Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene. Maturitas 50: 321-330, 2005
34. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, Dossus L, Micheli A, Arslan A, Lenner P, Shore RE, Krogh V, Koenig KL, Riboli E, Berrino F, Hallmans G, Stattin P, Toniolo P, Kaaks R: Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150: 161-171, 2004
35. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90: 1292-1299, 1998
36. Dorgan JF, Baer DJ, Albert PS, Judd JT, Brown ED, Corle DK, Campbell WS, Hartman TJ, Tejpar AA, Clevidence BA, Giffen CA, Chandler DW, Stanczyk FZ, Taylor PR: Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst 93: 710-715, 2001
37. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, Pelletier G: Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24: 152-182, 2003
38. Bajetta E, Martinetti A, Zilembo N, Pozzi P, La Torre I, Ferrari L, Seregni E, Longarini R, Salvucci G, Bombardieri E: Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol 13: 1059-1066, 2002